Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR)

被引：31

作者：

Nagel, S ^{[1
]}

Schmidt, M ^{[1
]}

Thiede, C ^{[1
]}

Huhn, D ^{[1
]}

Neubauer, A ^{[1
]}

机构：

[1] HUMBOLDT UNIV BERLIN, FAK MED, KLINIKUM RUDOLF VIRCHOW, ABT INNERE MED S HAMATOL & ONKOL, D-13353 BERLIN, GERMANY

来源：

NUCLEIC ACIDS RESEARCH | 1996年 / 24卷 / 20期

关键词：

D O I：

10.1093/nar/24.20.4102

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The quantification of Bcr-Abl transcript numbers in chronic myelogenous leukemia (CML) patients described here uses simultaneous competitive PCR amplification of the target gene (Bcr-Abl) and a reference gene (porphobilinogen deaminase; Pbgd) together with a single composite competitor molecule for both targets based on heterologous sequences, Using this technique, Bcr-Abl transcript numbers could be reproducibly determined even in clinical samples known to harbour poor quality RNA.

引用

页码：4102 / 4103

页数：2

共 7 条

[1] DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE [J].